Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists hunt for clues to tell apart two Look-Alike lymphomas

NCT ID NCT07313943

Knowledge-focused Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at rare lymphomas that are hard to tell apart under the microscope—some look like Hodgkin lymphoma but lack a key marker (PAX5), making them similar to another type called anaplastic large cell lymphoma (ALCL). Researchers will analyze tissue samples from 60 adults to find genetic and protein patterns that can better distinguish these two diseases. The goal is to improve diagnosis, since the two types have very different survival rates and treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Dec 2025

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

It is planned to enroll patients who have referred for diagnosis, from January 2014 to March 2025, at the following hospitals: 1) SSD of Hemolymphopathology IRCCS - Azienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola-Malpighi and 2) the Pathological Anatomy of Tübingen, Germany

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with lymphoma diagnosed as classic Hodgkin's lymphoma with a negative PAX5 marker * Patients with uncertain differential diagnosis between classical Hodgkin's lymphoma with atypical phenotype (PAX5 negative) and ALK-negative anaplastic large T-cell lymphoma (PAX5 negative) * Adult males and females at diagnosis * Availability of the molecular and/or cytogenetic data. Exclusion Criteria: * Patients with a diagnosis other than that under study, for whom clinical/histological/molecular information is not available

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALK-negative anaplastic large cell lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ALK-negative anaplastic large cell lymphoma classic Hodgkin lymphoma lymphoma non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hodgkin or non-Hodgkin lymphoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites in 2 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Irccs Azienda Ospedaliero-Universitaria Di Bologna

    RECRUITING

    Bologna, 40138, Italy

  • Universitätsklinikum Tübingen Institut für Pathologie

    RECRUITING

    Tübingen, 72076, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.